Physician profile
Kenneth Mark Brooks
NPI 1073604435
$3,595.27
in general payments reported to CMS, 2019-2025
31 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $100 · 2021: $395 · 2022: $652 · 2023: $1,368 · 2024: $317 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $478.08 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $410.25 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $300.17 | 2019-2024 | |
| Pfizer INC. | $290.85 | 2019-2023 | |
| Amgen INC. | $288.01 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $261.52 | 2019-2024 | Xarelto |
| Abbott Laboratories | $168.55 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Amarin Pharma, INC. | $139.16 | 2019-2021 | |
| Chiesi USA, INC. | $137.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $131.13 | 2021-2023 | Camzyos, Eliquis |
| Enterra Medical, INC. | $117.63 | 2024 | |
| Esperion Therapeutics, INC. | $112.50 | 2021-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $108.85 | 2019-2024 | Wainua |
| Medicomp INC | $103.60 | 2023-2024 | Telepatch Cardiac Monitor |
| Kowa Pharmaceuticals America, INC. | $65.29 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $62.92 | 2022-2024 | Bodyguardian |
| Sanofi-Aventis U.S. LLC | $61.43 | 2021-2023 | |
| Scpharmaceuticals INC. | $50.47 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.32 | 2023 | Lifevest |
| Medtronic Vascular, INC. | $38.05 | 2019 | |
| Atricure, INC. | $28.95 | 2023 | |
| Cardiovascular Systems INC. | $24.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.39 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.93 | 2023 | Inpefa |
| Biocompatibles, INC. | $21.42 | 2019 | |
| Daiichi Sankyo INC. | $20.91 | 2023 | Injectafer |
| Philips North America LLC | $18.78 | 2022 | |
| Lilly USA, LLC | $17.64 | 2024 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $17.32 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.60 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $14.52 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.